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S U M M A R Y
Introduction: The aims of this study were (1) to assess the incidence of ventilator-associated pneumonia
(VAP) in patients with traumatic brain injury (TBI), (2) to identify risk factors for developing VAP, and (3)
to assess the prevalence of the pathogens responsible.
Patients and methods: The following data were collected prospectively from patients admitted to a 24-
bed intensive care unit (ICU) during 2013/14: the mechanism of injury, trauma distribution by system,
the Acute Physiology and Chronic Health Evaluation (APACHE) II score, the Abbreviated Injury Scale (AIS)
score, the Injury Severity Score (ISS), underlying diseases, Glasgow Coma Scale (GCS) score, use of
vasopressors, need for intubation or cardiopulmonary resuscitation upon admission, and presence of
pulmonary contusions. All patients were managed with a standardized protocol if VAP was suspected.
The Sequential Organ Failure Assessment (SOFA) score and the Clinical Pulmonary Infection Score (CPIS)
were measured on the day of VAP diagnosis.
Results: Of the 144 patients with TBI who underwent mechanical ventilation for >48 h, 49.3% did not
develop VAP, 24.3% developed early-onset VAP, and 26.4% developed late-onset VAP. Factors
independently associated with early-onset VAP included thoracic injury (odds ratio (OR) 8.56, 95%
conﬁdence interval (CI) 2.05–35.70; p = 0.003), ISS (OR 1.09, 95% CI 1.03–1.15; p = 0.002), and coma upon
admission (OR 13.40, 95% CI 3.12–57.66; p < 0.001). Age (OR 1.04, 95% CI 1.02–1.07; p = 0.002), ISS (OR
1.09, 95% CI 1.04–1.13; p < 0.001), and coma upon admission (OR 3.84, 95% CI 1.44–10.28; p = 0.007)
were independently associated with late-onset VAP (Nagelkerke r2 = 0.371, area under the curve (AUC)
0.815, 95% CI 0.733–0.897; p < 0.001). The 28-day survival rate was 69% in the non-VAP group, 45.7% in
the early-onset VAP group, and 31.6% in the late-onset VAP group. Acinetobacter spp was the most
common pathogen in patients with early- and late-onset VAP.
Conclusions: These results suggest that the extent of TBI and trauma of other organs inﬂuences the
development of early VAP, while the extent of TBI and age inﬂuences the development of late VAP.
Patients with early- and late-onset VAP harboured the same pathogens.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Traumatic brain injury (TBI) is a serious condition associated
with a prolonged hospital admission and high mortality.1 Patients
with TBI may also have an airway obstruction, aspiration, or
hypoxia.2,3 Intubation and mechanical ventilation (MV) are
indicated for many patients with severe TBI.3
Ventilator-associated pneumonia (VAP) is a type of nosocomial
pneumonia that occurs in patients who receive >48 h of MV. Early-
onset VAP occurs during the ﬁrst 4 days of MV and is usually
caused by antibiotic-sensitive bacteria. The increased systemic
inﬂammatory response in patients with a head trauma may
predispose them to develop early-onset VAP.4,5 Late-onset VAP
develops 5 days after initiating MV and is caused by multidrug-
resistant (MDR) pathogens.6,7
Patients with TBI are at high risk of infection, particularly
nosocomial infections, during treatment in the intensive care unit
(ICU), where the incidence of VAP can be as high as 50%.8–10
The duration of MV usually inﬂuences the type of organism that
causes VAP.11 Early-onset VAP is caused by antibiotic-sensitive
pathogens, whereas late-onset VAP is caused by MDR bacteria,
which are more difﬁcult to treat. The microbiological environment
can have a marked inﬂuence on VAP isolates, particularly during
late-onset VAP, but it also inﬂuences early-onset VAP.12
Patients who acquire VAP have longer ICU stays, higher
morbidity and mortality, and a greater number of infectious
agents.13,14
The risk factors for developing VAP are diverse, and the
pathogenesis of intra-hospital infections is complex. Common VAP
preventive measures such as early mobility, the daily interruption
of sedation, and a readiness-to-extubate assessment may not be
applicable because of associated injuries such as severe chest
trauma, intra-abdominal bleeding, and other organ damage.
Hence, VAP diagnosis can be difﬁcult in a setting of multiple
trauma, and signiﬁcant variations in the diagnosis and manage-
ment of VAP remain.11
The primary objectives of this study were to assess the incidence
of VAP in patients with TBI and to identify risk factors for developing
VAP in this speciﬁc patient population (types of co-injuries in
patients with multiple trauma or characteristics on admission). The
secondary objective was to assess the prevalence of pathogens
responsible for early- and late-onset VAP in patients with TBI.506  paent s wit
TBI
144 paent s 
enrolled
71 no VAP 35 early-onset VAP
38 late-onset
VAP
Figure 1. Patient sel2. Patients and methods
2.1. Study population and design
A prospective observational cohort study was conducted in a
multidisciplinary (medical, surgical, and trauma) ICU at the
University Emergency Centre, Clinical Centre of Serbia, Belgrade,
Serbia; this ICU has 24 beds. Data recorded prospectively in the
database for the surveillance of nosocomial infections were
reviewed from January 2013 to December 2014; all consecutive
VAP episodes with identiﬁed isolates were documented. This study
was approved by the Ethics Committee of the Medical Faculty at
the University of Belgrade, Serbia (No. 29/IV-14).
2.2. Evaluation on admission
The records of all patients with TBI who were on MV for >48 h
after the initial evaluation were reviewed. Patients were trans-
ferred either from the emergency room directly to the ICU, or they
were transferred to the operating room ﬁrst and were then
admitted to the ICU after surgery. A total of 506 patients with TBI
were identiﬁed during the study period (Figure 1). Patients with
documented gastric aspiration, recent antibiotic therapy, 2 days
of hospitalization in the preceding 30 days, residence in a nursing
home or extended care facility, home therapy, or an underlying
malignancy were excluded. In total, 204 patients were transported
from another hospital but were excluded due to incomplete data.
Patients who were transferred within the hospital if there was an
accident or change in the ventilator system, or who had other
known risk factors for developing pneumonia, were also excluded.
Patients intubated outside the hospital and who had no side effects
were not excluded.
Data collected at admission included the mechanism of injury
(blunt or penetrating trauma), trauma distribution by system (head,
thoracic, abdomen, etc.), the Acute Physiology and Chronic Health
Evaluation (APACHE) II score, the Abbreviated Injury Scale (AIS)
score, the Injury Severity Score (ISS), and the patient’s underlying
diseases. Factors such as shock, coma (Glasgow Coma Scale (GCS)
score <9), multiple transfusions, use of vasopressors, need for
intubation or cardiopulmonary resuscitation on admission, emer-
gency or elective surgery, and the presence of pulmonary contusions
on chest X-ray at admission were recorded.h 
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patients who did not develop VAP, those who developed early-
onset VAP, and those who developed late-onset VAP.
2.3. Treatment
The trauma patients were treated by a team that included a
neurosurgeon, trauma surgeon, maxillofacial surgeon, orthopaedic
surgeon, a radiologist, an intensive care physician, and a
physiotherapist. The decision to monitor intracranial pressure
(ICP) was made by the neurosurgeon. All patients underwent an
emergency brain computed tomography scan. Intracranial hyper-
tension was treated with mannitol with or without a craniotomy. A
third-generation cephalosporin (ceftriaxone) and metronidazole
were administered as antibiotic prophylaxis for accompanying
wound injuries (skin and soft tissue).
VAP preventive strategies performed in the ICU include daily
interruption of sedation and a readiness-to-extubate assessment,
early facilitation of mobility, elevating the head of the bed to 30–
458, use of endotracheal tubes with subglottic secretion drainage
ports and a closed/in-line endotracheal suctioning system, change
of the ventilator circuit if visibly soiled or malfunctioning, stress
ulcer prophylaxis, residual gastric volume monitoring, early
parenteral nutrition, and deep venous thrombosis prophylaxis.
An infusion of midazolam and propofol was used for sedation, and
remifentanil was infused for analgesia.
2.4. Diagnosis and outcomes
The clinical, radiographic, and laboratory data of all patients
were reviewed daily for the development of pneumonia. The chest
X-rays were interpreted by a radiologist. The VAP diagnosis was
made by the intensive care physician. All patients were managed
with a standardized protocol if VAP was suspected.13,15 The
Sequential Organ Failure Assessment (SOFA) score and the Clinical
Pulmonary Infection Score (CPIS) were measured on the day of VAP
diagnosis.
Respiratory samples for a bacteriological examination were
usually collected from tracheobronchial aspirates. Bronchoalveolar
lavage (BAL) ﬂuid was used only when BAL would not increase the
hypoxia severity to a dangerous level or increase ICP. Protected
specimen brushes are not used routinely in this patient population.
Respiratory samples were quantitatively cultured according to
standard microbiological laboratory procedures. Samples with a
neutrophil count <25 and/or >10 squamous epithelial cells in the
ﬁeld were deﬁned as contaminated. Microbiological conﬁrmation
of VAP was deﬁned as the presence of at least one potentially
pathogenic microorganism in the respiratory sample at predeﬁned
thresholds (104 colony-forming units (CFU)/ml in BAL ﬂuid, or 106
CFU/ml in a tracheobronchial aspirate). Samples with numbers of
microorganisms under these thresholds were excluded because of
low speciﬁcity.
Antibiotics were changed based on the microbiological ﬁndings
of the BAL ﬂuid or tracheobronchial aspirate.
2.5. Deﬁnitions
Trauma was deﬁned as the presence of TBI either as an isolated
injury or associated with other injuries and a need for ICU
admission and/or surgery. Disease severity was evaluated in all
patients using the APACHE II score during the ﬁrst 24 h of ICU
admission. The VAP diagnosis was based on chest radiographic,
systemic infection, and pulmonary criteria. The chest radiography
criteria included a new pulmonary inﬁltrate, worsening of X-ray
ﬁndings in patients with a contusion, pleural effusion, or
cavitation. The systemic criteria were fever >38 8C, leukopenia(white blood cell count <4  109/ml), or leukocytosis (white blood
cell count >12  109/ml). The pulmonary criteria were new-onset
purulent sputum (or change in the sputum character, increased
respiratory secretions, or increased suctioning requirement),
worsening gas exchange (desaturation, increased oxygen require-
ment, or increased ventilator demand), new onset or worsening
cough, dyspnoea or tachypnoea, and rales or bronchial breath
sounds.
Pneumonia was considered early onset if it occurred within 2–4
days. Patients with very early onset pneumonia were deﬁned as
those who developed the infection within the ﬁrst 48 h and were
not included in the study. Late-onset pneumonia began on day 5 or
later after admission.13
The CPIS considers clinical and radiographic data to determine a
numerical value that predicts the presence or absence of VAP; a
score 6 has a good correlation with the presence of VAP.16 Coma
was diagnosed when the GCS score was <9 (both sedation and
non-sedation) for more than 24 h. Acute respiratory distress
syndrome was diagnosed according to the Berlin deﬁnition
criteria.17 Shock was deﬁned as systolic blood pressure <90 mmHg
mHg despite adequate ﬂuid resuscitation and the need for
vasopressor agents. Polytransfusion was deﬁned as the need for
>10 units of packed red cells within 24 h. Pulmonary contusion
was deﬁned by a radiologist on a chest X-ray. The AIS was used to
compare injuries. The AIS is the most widely used anatomic scale
for rating injury severity18,19 and has historically been used in
conjunction with the ISS to identify the effects of multiple injuries
on trauma victims.20
2.6. Statistical analysis
Data are presented as the mean (standard deviation) for
continuous variables and as the frequency (%) for categorical
variables. The t-test was used for the two-group mean comparisons
(early-onset VAP vs. without VAP, and late-onset VAP vs. without
VAP). Categorical data were compared using Pearson’s Chi-square
test or Fisher’s exact test, where appropriate. Two logistic
regression analyses were performed to investigate the associations
between demographics, the injury and clinical characteristics of
the patients at admission to the ICU, and the probability of VAP
onset. Each patient characteristic (age, sex, and pre-existing
medical conditions), injury characteristics and severity (type
and number of injuries, injured body regions, AIS, and ISS), and
clinical characteristics (presence of haemorrhagic shock, coma, or
pulmonary contusion on admission and sustaining reanimation,
multiple transfusions, surgery, or vasopressor use) were analysed
in a univariate logistic regression analysis. Variables that were
signiﬁcantly associated with the onset of VAP in the univariate
analysis, with a p-value of <0.1, were entered into a multivariate
model, and stepwise logistic regression was performed. Odds
ratios (OR) with 95% conﬁdence intervals (CI) were computed, and
Pearson’s goodness-of-ﬁt test was performed to assess overall
model ﬁt. Measures of discrimination (Nagelkerke r2 and area
under the receiver operating characteristic curve (AUC)) were
calculated for all regression models. All statistical tests were two-
sided and were performed at the 5% signiﬁcance level. The
statistical analysis was performed using IBM SPSS Statistics version
20.0 software (IBM Corp., Armonk, NY, USA).
3. Results
3.1. Characteristics of the patients with TBI
Of the 144 patients with TBI (with or without additional injury)
who underwent MV for >48 h, 71 (49.3%) did not develop VAP, 35
(24.3%) developed early-onset VAP, and 38 (26.4%) developed
B. Jovanovic et al. / International Journal of Infectious Diseases 38 (2015) 46–51 49late-onset VAP. No patient was diagnosed with more than one
episode of VAP and all had positive microbiological ﬁndings.
Table 1 compares the demographic, injury, and clinical
characteristics of the patients in the three groups. Patients who
developed early-onset VAP were signiﬁcantly younger (36.5  15 vs.
53.1  20 years; p < 0.001), and a lower number presented with a pre-
existing condition (11.4 vs. 45.1%; p < 0.001) compared to those
without VAP; they also had fewer pre-existing conditions (31% vs. 39%;
p < 0.003) and had less frequent cardiac disease (2.9% vs. 33.8%;
p < 0.001) than those without VAP. Patients with early-onset VAP had
less isolated TBI and a greater number of additional injuries (8.6% vs.
38%; p < 0.01), had more frequent thoracic (74.3% vs. 31%; p < 0.01),
abdominal (37.1% vs. 12.7%; p = 0.03), and spinal injuries (34.3% vs.
12.7%; p < 0.0009), and had more frequent AIS scores 3 for the head
(77.1% vs. 52.1%; p = 0.013), thorax (57.1% vs. 8.5%; p < 0.001), andTable 1
Characteristics of patients with TBI on admission to the ICU
Without VAP Early-on
(n = 71) (n = 35) 
General characteristics
Age, years, mean (SD) 53.1 (20) 36.5 (15)
Male, n (%) 59 (83.1) 28 (80.0)
Comorbidities, n (%) 32 (45.1) 4 (11.4)
No. of comorbidities, n (%)
0 39 (54.9) 31 (88.6)
1 19 (26.8) 2 (5.7) 
2 13 (18.3) 2 (5.7) 
Comorbidity, n (%)
COPD 1 (1.4) 1 (2.9) 
Asthma 2 (2.8) 0 (0.0) 
Chronic renal disease 3 (4.2) 2 (5.7) 
Chronic liver disease 3 (4.2) 1 (2.9) 
Chronic immune suppression 2 (2.8) 1 (2.9) 
Diabetes 9 (12.7) 2 (5.7) 
Cardiac disease 24 (33.8) 1 (2.9) 
Injury characteristics
Type of injury, n (%)
Blast 67 (94.4) 34 (97.1)
Penetrating 4 (5.6) 1 (2.9) 
Number of injured systems, n (%)
TBI only 27 (38.0) 3 (8.60)
TBI +1 23 (32.4) 7 (20.0)
TBI +2 11 (15.5) 11 (31.4)
TBI +3 10 (14.1) 14 (40.0)
Injury by system, n (%)
Face 25 (32.5) 13 (37.1)
Thorax 22 (31.0) 26 (74.3)
Abdomen 9 (12.7) 13 (37.1)
Extremities/pelvis 14 (19.7) 11 (31.4)
Spine 9 (12.7) 12 (34.3)
AIS 3, n (%)
Head 37 (52.1) 27 (77.1)
Face 21 (29.6) 8 (22.9)
Thorax 6 (8.5) 20 (57.1)
Abdomen 6 (8.5) 4 (11.4)
Extremities 13 (18.3) 14 (40.0)
ISS, mean (SD) 17.8 (10) 32.0 (13)
Clinical characteristics
On admission, n (%)
Haemorrhagic shock 7 (9.9) 9 (25.7)
Vasopressor use 3 (4.2) 4 (11.4)
Multiple transfusion 4 (5.6) 6 (17.1)
Coma (GCS <9) 30 (42.3) 25 (71.4)
Surgery (urgent/elective) 26 (36.6) 13 (37.1)
Pulmonary contusion on admission 9 (12.7) 21 (60.0)
Reanimation 0 (0.0) 0 (0.0) 
APACHE II, mean (SD) 14.0 (6) 16.1 (6) 
TBI, traumatic brain injury; ICU, intensive care unit; VAP, ventilator-associated pneum
Abbreviated Injury Scale score; ISS, Injury Severity Score; GCS, Glasgow Coma Scale sc
a Clinical Pulmonary Infection Score (CPIS), mean (SD) 7.9 (3.3) vs. 9.7 (4.6); p > 0.05. 
p > 0.05.
b For comparison between ‘without VAP’ and ‘early-onset VAP’.
c For comparison between ‘without VAP’ and ‘late-onset VAP’.extremities (40% vs. 18.3%; p = 0.016), as well as more frequent mean
ISS scores 3 (32  13 vs. 17.8  10; p < 0.001) compared to those
without VAP. More patients with early-onset VAP presented with
haemorrhagic shock (25.7% vs. 99.9%; p = 0.032), coma (GCS <9 71.4%
vs. 42.3%; p = 0.005), and pulmonary contusions (60% vs. 12.7%; p <
0.001%) on admission than patients without VAP.
Patients with late-onset VAP were signiﬁcantly older (64.7 
15 vs. 36.5  15 years; p = 0.001), had more frequent head AIS 3
(76.3% vs. 52.1%; p = 0.014), and more patients had higher mean ISS 3
(27.1  15 vs. 17.8  10; p < 0.001) compared to patients without VAP.
Patients with late-onset VAP presented more frequently with coma on
admission (GCS <9 71.1% vs. 42.3%; p = 0.004) and were subject to
reanimation (7.9% vs. 0%; p = 0.040) and multiple transfusions (21.1%
vs. 5.6%; p = 0.023) in greater numbers than patients without VAP. In
addition, patients with late-onset VAP had a more severe overall clinicalset VAPa p-Valueb Late-onset VAPa p-Valuec
(n = 38)
 <0.001 64.7 (15) 0.001
 0.696 28 (73.7) 0.243
 0.001 22 (57.9) 0.202
 0.003 16 (42.1) 0.258
16 (42.1)
6 (15.8)
1.000 1 (2.6) 1.000
1.000 1 (2.6) 1.000
1.000 3 (7.9) 0.418
1.000 0 (0.0) 0.550
1.000 0 (0.0) 0.542
0.332 6 (15.8) 0.653
<0.001 16 (42.1) 0.391
 1.000 36 (94.7) 0.936
2 (5.3)
 <0.001 11 (28.0) 0.597
 11 (28.9)
 9 (23.7)
 7 (18.4)
 0.845 15 (39.5) 0.660
 <0.001 16 (42.1) 0.246
 0.003 5 (13.2) 0.943
 0.182 10 (26.3) 0.428
 0.009 6 (15.8) 0.653
 0.013 29 (76.3) 0.014
 0.465 13 (34.2) 0.619
 <0.001 6 (15.8) 0.336
 0.727 3 (7.9) 0.920
 0.016 11 (28.9) 0.202
 <0.001 27.1 (15) 0.001
 0.032 7 (18.4) 0.236
 0.215 5 (13.2) 0.124
 0.078 8 (21.1) 0.023
 0.005 27 (71.1) 0.004
 0.958 12 (31.6) 0.599
 <0.001 9 (23.7) 0.140
NA 3 (7.9) 0.040
0.091 18.4 (6) 0.001
onia; SD, standard deviation; COPD, chronic obstructive pulmonary disease; AIS,
ore; APACHE, Acute Physiology and Chronic Health Evaluation score.
Sequential Organ Failure Assessment (SOFA) score, mean (SD) 6.3 (1.6) vs. 6.6 (1.5);
Table 2
Factors associated with early-onset of VAP
Unadjusted model Age-adjusted model
b (SE) OR (95% CI) p-Value b (SE) OR (95% CI) p-Value
Cardiac disease 3.56 (1.27) 0.03 (0.01–0.35) 0.005 2.31 (1.44) 0.10 (0.01–1.66) 0.108
Injury of thorax 2.15 (0.73) 8.56 (2.05–35.70) 0.003 2.31 (0.76) 10.04 (2.26–44.68) 0.002
ISS 0.08 (0.03) 1.09 (1.03–1.15) 0.002 0.08 (0.03) 1.08 (1.03–1.14) 0.004
Coma 2.60 (0.75) 13.40 (3.12–57.66) <0.001 2.51 (0.75) 12.29 (2.83–53.46) 0.001
VAP, ventilator-associated pneumonia; SE, standard error; OR, odds ratio; CI, conﬁdence interval; ISS, Injury Severity Score.
Table 4
Distribution of causative agents of VAP, isolated from respiratory samples
Pathogen Early-onset VAP Late-onset VAP
B. Jovanovic et al. / International Journal of Infectious Diseases 38 (2015) 46–5150state on admission, as indicated by a higher mean APACHE II score
(18.4  6 vs. 14.0  6; p = 0.001). However, the two groups did not
differ in the numbers of comorbidities, injured body regions, or the
presence of pulmonary contusions at admission.
3.2. Factors associated with early-onset VAP
After including all signiﬁcant variables from the univariate
logistic regression into the multivariate model, four variables were
found to be independently associated with early-onset VAP,
including absence of cardiac disease (OR 0.03, 95% CI 0.01–0.35;
p = 0.005), thoracic injury (OR 8.56, 95% CI 2.05–35.70; p = 0.003),
ISS (OR 1.09, 95% CI 1.03–1.15; p = 0.002), and coma on admission
(OR 13.40, 95% CI 3.12–57.66; p < 0.001). Age was returned to the
model to control for the potential confounding effects of age on the
association between cardiac disease and early-onset VAP. The
crude and age-adjusted models are presented in Table 2. As
expected, the absence of cardiac disease was no longer associated
with the onset of VAP after adjusting for age, as the risk estimates
became insigniﬁcant (adjusted OR 1.10, 95% CI 0.01–1.66;
p = 0.108). The Nagelkerke r2 for the adjusted model was 0.641,
and the AUC was 0.921 (95% CI 0.862–0.980; p < 0.001).
3.3. Factors associated with late-onset VAP
Table 3 show the logistic regression results to examine the
factors associated with developing late-onset VAP. Age (OR 1.04,
95% CI 1.02–1.07; p = 0.002), ISS (OR 1.09, 95% CI 1.04–1.13;
p < 0.001), and coma on admission (OR 3.84, 95% CI 1.44–1.28;
p = 0.007) were independently associated with late-onset VAP
(Nagelkerke r2 = 0.371; AUC 0.815, 95% CI 0.733–0.897; p < 0.001).
The BAL ﬂuid microbiology ﬁndings are presented in Table 4.
Acinetobacter spp was the most common pathogen encountered in
both patients with early-onset and late-onset VAP.
4. Discussion
The 49.7% incidence of VAP in patients with severe TBI in this
study is very high, but similar to that of a previous study.15 The
results of the present study demonstrated injury severity to be an
independent risk factor for developing VAP, particularly in patients
with multiple trauma. Patients who developed VAP had very high
AIS scores (3 points) for head injury (77.1% in the early-onset and
76.3% in late-onset VAP groups). These data demonstrate that the
system injured with the TBI, particularly a chest injury, is anTable 3
Factors associated with late-onset of VAP
b (SE) OR (95% CI) p-Value
Age 0.04 (0.02) 1.04 (1.02–1.07) 0.002
ISS 0.08 (0.02) 1.09 (1.04–1.13) 0.000
Coma 1.35 (0.50) 3.84 (1.44–10.28) 0.007
VAP, ventilator-associated pneumonia; SE, standard error; OR, odds ratio; CI,
conﬁdence interval; ISS, Injury Severity Score.independent factor for the development of early-onset VAP. Other
important factors associated with the development of early-onset
VAP are abdominal trauma and a spinal injury. The results suggest
that underlying disease, such as a coronary condition and the
trauma severity with an isolated brain or chest injury, should be
considered in the therapeutic decision for patients with VAP.
A unique feature of this study is that the subpopulation of
patients who developed early-onset VAP were signiﬁcantly
younger (mean age 33 years) compared to those who did not
develop VAP (mean age 50 years) and those who developed late-
onset VAP (mean age 63.5 years). Although the cause of injury was
not recorded, severe car and motorbike accidents, assaults, and
falls are known to be speciﬁc for the young population in this
region. About 75% of the early-onset VAP subpopulation had a
chest trauma and 57.1% had an AIS score 3 points for chest
trauma. The incidence of early-onset VAP increased in patients
who had more systems injured with TBI.
The data from this study demonstrated that a GCS <9 on
admission was associated with a higher incidence of developing
VAP, which can be explained by the severity of the brain injury, the
need for emergency intervention, and prolonged sedation with
MV. It was also demonstrated that 60% of patients who developed
early-onset VAP had pulmonary contusions on admission, which is
signiﬁcant, particularly when compared with those who developed
late-onset VAP (23.7%).
The high incidence of MDR remains a problem and a burden of
regional centres and ICUs and depends on the local ecology.21,22
Antimicrobials used in empirical regimens should be selected
based on the local pattern of susceptibility. Despite the fact that
most MDR bacteria are isolated from patients with late-onset VAP,
there is growing evidence that resistance is also a problem in
patients who develop early-onset VAP.16
Another important ﬁnding of this study was the lack of a
difference between isolated pathogens. This is a new problem,
particularly concerning empirical antimicrobial therapy, because
the pathogens that cause early- and late-onset VAP are similar.23
Staphylococcus aureus appears to be a typical pathogen of early-
onset pneumonia in younger patients with head trauma, due to the
incidence of S. aureus nasal carriage on admission.24,25 In theAcinetobacter spp 24 (47.2) 29 (51.8)
Klebsiella pneumoniae 8 (15.7) 10 (17.9)
Pseudomonas aeruginosa 5 (9.8) 9 (16.1)
Staphylococcus aureus (MSSA) 6 (11.7) -
Staphylococcus aureus (MRSA) 2 (3.9) 4 (7.1)
Serratia spp 3 (5.9) 1 (1.8)
Citrobacter spp 2 (3.9) 1 (1.8)
Enterobacter spp - 1 (1.8)
Stenotrophomonas maltophilia 1 (1.9) 1 (1.8)
Total 51 (100%) 56 (100%)
VAP, ventilator-associated pneumonia; MSSA, methicillin-sensitive Staphylococcus
aureus; MRSA, MSSA, methicillin-resistant Staphylococcus aureus.
B. Jovanovic et al. / International Journal of Infectious Diseases 38 (2015) 46–51 51present study, Acinetobacter spp was the most prevalent microor-
ganism isolated from patients with early- and late-onset VAP
(47.2% and 51.8%), followed by Klebsiella pneumoniae (15.7% and
17.9%) and Pseudomonas aeruginosa (9.8% and 16.1%). Methicillin-
sensitive S. aureus was isolated only from patients with early-onset
VAP. However, the incidence of methicillin-resistant S. aureus in
both subgroups was similar: two cases in early-onset VAP (3.9% of
isolates) and four cases in late-onset VAP (7.1% of isolates).
The present ﬁndings regarding the incidence of isolation of
pathogens are not applicable to other centres. Despite growing
evidence that there is no difference between the clinical courses of
early- and late-onset VAP,26 a signiﬁcant association was found
between severe TBI associated with a chest injury and early
pulmonary infection as a serious complication, with no difference in
mortality rate. Geographic variation may potentiate the likelihood of
a patient developing VAP, and possibly other types of nosocomial
infection. The environmental characteristics of patients may
predispose certain populations to infection in the setting of trauma,
and the prevention of such infections may not be possible.27
The proportion of patients who developed VAP in this study was
slightly higher than reported previously.28,15 The VAP rate
observed occurred after implementing a regional and multidisci-
plinary VAP preventive program with standardized diagnostic
algorithms and a revised regional policy according to evidence-
based recommendations for preventing VAP.
The secondary analysis had several limitations that should be
addressed. First, a high mortality rate was reported, primarily due
to sepsis, which was either a consequence of extensive brain injury,
VAP, or infection of other organs. Second, factors not included in
the study may have contributed to the high incidence of VAP, such
as alcohol abuse, severity of fall or motor vehicle collision, and ICU
work patterns and setting. Third, distinguishing infectious
pneumonia (IP), aspiration pneumonia (AP), and VAP in patients
with TBI is difﬁcult,31 especially in an administrative dataset. The
lack of microbiological data and the likely presence of multiple
other confounders could not be identiﬁed or controlled for in this
study.30 Many of the factors associated with an increased risk of
VAP are inherent comorbidities in patients with TBI that place this
unique group at high risk.30
The results of the present study demonstrate that patients with
TBI are at increased risk of developing pneumonia and that a
signiﬁcant portion of this risk is associated with an extended time
on MV, as such patients may be ventilated for days or weeks.31
The ISS and coma were independent predictors of early- and
late-onset VAP in patients with TBI. Additionally, young age and
chest trauma were predictors of early-onset VAP, whereas older
age was a predictor of late-onset VAP.
In summary, patients with severe TBI and a chest injury
represent a speciﬁc subgroup of patients with a higher risk of
developing early-onset VAP, possibly caused by antibiotic-resis-
tant pathogens. These patients are a speciﬁc target population for
studies examining the prevention and treatment of pneumonia.
Acinetobacter spp was the leading cause of pneumonia in patients
with severe TBI in this study. In conclusion, the results of this study
suggest that the extent of TBI and trauma of other organs inﬂuence
the development of early VAP, while the extent of TBI and age
inﬂuence the development of late VAP. Patients with early- and
late-onset VAP harboured the same pathogens.
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